Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
While the cardiovascular (CV) benefits with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes mellitus (DM) are well known, their effects in patients without DM continue to be explored. We provide a meta-analysis of the available evidence. Online databases were searched for randomized controlled trials (RCTs) comparing SGLT2i to placebo/control in patients without DM. The endpoints of interest were composite CV death/hospitalization for heart failure (HF) with individual components, all cause death, major adverse CV events (MACE) and serious adverse events.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Sahib Singh, Aakash Garg, Udaya S Tantry, Kevin Bliden, Paul A Gurbel, Martha Gulati Source Type: research
More News: Cardiology | Cardiovascular | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Empagliflozin | Endocrinology | Forxiga | Heart | Heart Failure | Jardiance | Sodium